Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer

摘要

The phase 3 {"type":"clinical-trial","attrs":{"text":"NCT00793962","term_id":"NCT00793962"}}NCT00793962 trial demonstrated that postmastectomy hypofractionated radiation therapy (HFRT) was noninferior to conventional fractionated radiation therapy (CFRT) in patients with high-risk breast cancer. This study assessed the cost-effectiveness of postmastectomy HFRT vs CFRT based on the {"type":"clinical-trial","attrs":{"text":"NCT00793962","term_id":"NCT00793962"}}NCT00793962 trial.